Results 231 to 240 of about 188,535 (344)

Therapeutic potential of TMSC-Exo for non-alcoholic fatty liver disease using the liver-on-a-chip model. [PDF]

J Transl Int Med
He S, Wang K, Li B, Fang W, Wei X, Yao F, Wang N, Wang X, Zhang Y, Gao Y, Li Y, Li S, Zhou S, Du J, Peng Q.   +14 more
europepmc   +1 more source

Additional file 2 of Human umbilical cord-derived mesenchymal stem cells ameliorate non-alcoholic fatty liver disease via activating TFEB-mediated autophagy in male mice

Huina Zhang, Peng Liu, Yaxuan Deng, Li Wu, Orion Fan, Yanling Cui, Ze Zhang, Wenmin Zhu, Yi Eve Sun, Chuwen Lin, Congrong Wang   +10 more
openalex   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

Chronic Periodontitis and Non-Alcoholic Fatty Liver Disease: Recent Advances in Mechanisms of Association. [PDF]

Int J Gen Med
Lyu Z, Zhu J, Chen D.
europepmc   +1 more source

A198 RELATIONSHIP BETWEEN HEPATIC GENE EXPRESSION AND MICROBIOME ACCORDING TO DISEASE SEVERITY IN OBESE PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE [PDF]

Y Ghorbani, Katherine J. P. Schwenger, Anastasia Teterina, Yanli Liu, Wendy Lou, Sandra E. Fischer, Timothy Jackson, Allan Okrainec, Johane P. Allard   +8 more
openalex   +1 more source

[P1–428]: NON‐ALCOHOLIC FATTY LIVER DISEASE AND CEREBRAL SMALL‐VESSEL DISEASE IN COGNITIVELY NORMAL INDIVIDUALS [PDF]

, 2017
Hyemin Jang, Danbee Kang, Yeshin Kim, Ko Woon Kim, Jin San Lee, Young Kyoung Jang, Duk L. Na, Hee Young Shin, Mira Kang, Eliseo Güallar, Juhee Cho, Sang Won Seo   +11 more
openalex   +1 more source

Advancing design strategies in smart stimulus‐responsive liposomes for drug release and nanomedicine

BMEMat, EarlyView.
Schematic illustration of stimulus‐responsive liposomes designed for controlled drug release and nanomedicine. The innermost circle represents different liposomal structures, including unilamellar, multilamellar, and multivesicular liposomes. The middle layer illustrates the responsive phospholipid components.
Yuchen Guo, Nan Li, Daiwei Zhang, Jingya Gu, Zhihuan Liao, Zihao Teng, Xiangfu Du, Peter S. Timashev, Shipeng Chen, Shuaidong Huo   +9 more
wiley   +1 more source

Life's essential 8 and non-alcoholic fatty liver disease: unmasking depressive symptoms' mediating role. [PDF]

Eur J Med Res
Liu S, Li X, Zeng S, Chen L, Wang Z, Luo X, Jing C.   +6 more
europepmc   +1 more source

Role of silymarin in the management of non-alcoholic fatty liver disease: Time to clear the mist

, 2019
Kuhu Roy, Uma Lyer
openalex   +2 more sources

Biomaterial design strategies for enhancing mitochondrial transplantation therapy

BMEMat, EarlyView.
Biomaterials to facilitate mitochondrial transplantation therapy: biomaterials as barriers to protect mitochondria from pathophysiological microenvironments, like osmotic stress caused by the excessive concentration of calcium ion, reactive oxygen species, and advanced glycation end products; biomaterials integrating with biochemical cues to improve ...
Shaoyang Kang, Yushan Zhang, Hang Li, Sirui Peng, Donghao Lyu, Chunxiao Zhou, Sheng Ding, Zujian Feng, Pingsheng Huang, Chuangnian Zhang, Hongjun Wang, Deling Kong, Weiwei Wang   +12 more
wiley   +1 more source